Clinical Trial Update: ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. [Phase 4]

View source ↗

Summary

Phase 4 study evaluating Pegasys (peginterferon alfa-2a) in combination with COPEGUS (ribavirin) in interferon-naive patients with chronic hepatitis C, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2016-01-21